Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST Substudy 7: tremelimumab in rare or neglected cancers
ACTRN12620000918921Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab in Nonhematologic neoplasms and cancer, sponsored by The University of Sydney. Primary endpoint: Progression-free survival at 6 months. Started Nov 2020; status: completed.
02
Drugs
tremelimumab
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on ACTRN12620000918921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000918921.